CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease

Neurology
T TapiolaH Soininen

Abstract

We quantified microtubule-associated protein tau in CSF (CSF tau) using ELISA assay in 168 subjects: 81 patients with clinically diagnosed early Alzheimer's disease (AD), 43 patients with other dementia, 11 Down's syndrome patients, and 33 nondemented neurologic control subjects. Multivariate ANOVA showed an effect of diagnostic group (p < 0.01) and apolipoprotein E (apoE) allele (p < 0.005) on CSF tau. Comparison between diagnostic groups showed higher CSF tau levels in AD than in the control group (p < 0.001). However, CSF tau values in the non-AD dementia group did not differ significantly from those of AD patients or neurologic control subjects. Tau levels were increased (p < 0.005) in AD patients with apolipoprotein E epsilon4 allele, a well-characterized risk factor of AD, compared with AD patients without epsilon4 allele, and the highest values were found in AD patients with two epsilon4 alleles. These increased levels of CSF tau may indicate pronounced neuronal degeneration and neurofibrillar pathology at the early stage of AD in patients carrying the epsilon4 allele. This study shows that the current ELISA test for CSF tau is not sensitive and specific enough to distinguish early AD from other dementias and indicates t...Continue Reading

References

Jul 1, 1989·Annals of Neurology·F M Yatsu, M Fisher
Jan 1, 1985·Annals of Neurology·H Creasey, S I Rapoport
Jan 6, 1995·The Journal of Biological Chemistry·R Taussig, A G Gilman
May 1, 1994·Nature Genetics
Jan 1, 1996·Journal of Neurology, Neurosurgery, and Psychiatry·I R Whittle
May 1, 1996·Journal of Neuropathology and Experimental Neurology·S S Chin, J E Goldman
Jan 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·J Schwinger

❮ Previous
Next ❯

Citations

Apr 12, 2002·Progress in Neurobiology·François Torreilles, Jacques Touchon
Dec 2, 1999·Neuroscience Letters·P D MehtaH M Wisniewski
Oct 5, 2013·ACS Chemical Neuroscience·Ming-Jang ChiuHong-Chang Yang
May 19, 2004·Clinical Chemistry and Laboratory Medicine : CCLM·Pierre R BurkhardIrmgard Irminger
Jun 1, 2006·Neuropsychiatric Disease and Treatment·Aoife HuntJohannes Schröder
Aug 1, 2008·Biomarkers in Medicine·Susanna Schraen-MaschkeLuc Buée
Sep 25, 2003·Lancet Neurology·Kaj Blennow, Harald Hampel
Jan 27, 1999·Annals of Medicine·H S Soininen, P Scheltens
Dec 18, 2001·Journal of Neuroscience Research·M SjögrenA Wallin
Jun 25, 2010·Neuroscience Letters·Ming FanUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Feb 27, 2003·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·E KapakiC Zournas
Feb 1, 2006·Journal of Cellular Physiology·Patrizia FormichiAntonio Federico
Dec 24, 2011·International Journal of Alzheimer's Disease·Rachna Agarwal, Chandra Bhushan Tripathi
Nov 11, 2003·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Niels AndreasenKaj Blennow
Apr 18, 2017·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Alain D DekkerPeter P De Deyn
Apr 11, 2001·Neurology·T TapiolaT Pirttilä

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alzheimer's Disease: APOE

Apolipoprotein E (APOE) polymorphic alleles are major genetic risk factors for Alzheimer's disease. Discover the latest research on APOE and other genetic determinants of Alzheimer's disease here.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.